文献速递淋巴瘤

利妥昔单抗时代结外I期弥漫大B细胞淋巴瘤的临床特征与结局

Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.
PubMed 文献 · Blood · 2021-01-01

这项回顾性研究纳入2001至2015年接受R-CHOP或R-CHOP类方案±放疗的341例I期弥漫大B细胞淋巴瘤患者,其中结外受累224例(66%)。结外受累与更差的OS(HR 3.44)和PFS(HR 3.25)相关;结外人群中巩固放疗与更好的OS(HR 0.26)和PFS(HR 0.35)相关,但免疫化疗结束时PET阴性者不再观察到该获益。

要点

  • 结外I期DLBCL较结内I期预后更差,OS的HR为3.44(95%CI 1.05-11.30)。
  • 结外人群中巩固放疗与更好OS(HR 0.26)和PFS(HR 0.35)相关。
  • 免疫化疗结束时PET阴性者未再观察到巩固放疗的获益。

核心结论

  • 结外I期DLBCL的结局较结内I期DLBCL更差。
  • 免疫化疗结束时PET结果可能有助于选择结外患者接受巩固放疗。

研究设计与样本

  • 回顾性研究,纳入2001至2015年诊断的I期DLBCL患者,接受R-CHOP或R-CHOP类方案伴或不伴放疗。
  • 共识别1955例新诊断DLBCL患者,其中341例为I期并纳入本分析。

主要发现

  • 结外受累224例(66%),结内受累117例(34%);最常见结外部位为骨21%、胃19%、睾丸9%、肠8%、乳腺8%。
  • 结外患者69%接受放疗,结内患者68%接受放疗;中位随访5.5年(四分位距4.3-8.2)。
  • 10年总生存(OS)为77%(95%CI 67%-83%),10年无病生存为77%(95%CI 68%-85%)。
  • 多变量分析中,与结内受累相比,结外受累与更差的OS相关(HR 3.44;95%CI 1.05-11.30),与更差的PFS相关(HR 3.25;95%CI 1.08-9.72)。
  • 结外人群中巩固放疗与更好的OS相关(HR 0.26;95%CI 0.12-0.49),与更好的PFS相关(HR 0.35;95%CI 0.18-0.69);但免疫化疗结束时PET阴性的患者中不再观察到该获益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This retrospective study aimed to better define the characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma (DLBCL) in the rituximab era. Patients diagnosed with stage I DLBCL from 2001 to 2015 treated with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) or R-CHOP-like regimens with or without radiation (RT) were included. We identified 1955 patients with newly diagnosed DLBCL, of whom 341 had stage I and were eligible for this analysis. Extranodal presentation was observed in 224 (66%) patients, whereas 117 (34%) had nodal involvement. The most common extranodal sites were as follows: bone, 21%; stomach, 19%; testis, 9%; intestine, 8%; breast, 8%. Overall, 69% extranodal patients and 68% nodal patients received RT. Median follow-up was 5.5 years (interquartile range, 4.3-8.2). Ten-year overall survival (OS) and disease-free survival were 77% (95% confidence interval [CI], 67%-83%) and 77% (95% CI, 68%-85%). In the multivariable analyses, extranodal involvement was associated with worse OS (hazard ratio [HR], 3.44; 95% CI, 1.05-11.30) and progression-free survival (PFS; HR, 3.25; 95% CI, 1.08-9.72) compared with nodal involvement. Consolidation RT was associated with better OS (HR, 0.26; 95% CI, 0.12-0.49) and PFS (HR, 0.35; 95% CI, 0.18-0.69) in the extranodal population; however, the benefit was no longer observed in patients that were positron emission tomography (PET) negative at the end of immunochemotherapy. Relapses occurred usually late (median, 37 months), and the most common sites were the lymph nodes (31%) and the central nervous system (27%). Extranodal stage I DLBCL had a worse outcome than nodal stage 1 DLBCL. End of immunochemotherapy PET results may help select extranodal patients for consolidation RT.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bobillo S, Joffe E, Lavery JA, et al. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. Blood. 2021. PMID: 32730585. doi:10.1182/blood.2020005112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。